Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Oct;51(10):1048-50.
doi: 10.1136/thx.51.10.1048.

Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease

R M Angus  1 , A A Ahmed, L J Fenwick, A J Peacock
Affiliations
Clinical Trial

Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease

R M Angus et al. Thorax. 1996 Oct.

Erratum in

  • Thorax 1997 Feb;52(2):204

Abstract

Background: Nasal intermittent positive pressure ventilation (NIPPV) is useful in exacerbations of chronic obstructive pulmonary disease (COPD) complicated by ventilatory failure. The effects of NIPPV were compared with those of the respiratory stimulant doxapram on gas exchange in patients with COPD and acute ventilatory failure.

Methods: Patients admitted with acute exacerbations of COPD and type 2 respiratory failure (Pao2 < 8 kPa and PaCO2 > 6.7 kPa) who did not improve with conventional treatment were randomised to receive either NIPPV or intravenous doxapram. Blood gas tensions were monitored for four hours.

Results: In nine patients who received NIPPV the arterial PaO2 improved from a mean (SE) of 5.9 (0.4) kPa to a maximum of 8.1 (0.6) kPa which was maintained at four hours. Eight patients who received doxapram had a similar baseline Pao2 of 5.6 (0.4) kPa which rose to a maximum of 7.3 (0.5) kPa but this was not maintained at four hours. The improvement in Pao2 in patients on NIPPV was accompanied by a fall in Paco2 but, in contrast, in those who received doxapram there was no improvement in Paco2.

Conclusions: NIPPV may be more effective than doxapram in the management of acute ventilatory failure complicating COPD.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1974 Apr;189(1):1-11 - PubMed
    1. Clin Sci (Lond). 1983 Jul;65(1):65-9 - PubMed
    1. BMJ. 1990 Feb 10;300(6721):358-60 - PubMed
    1. N Engl J Med. 1990 Nov 29;323(22):1523-30 - PubMed
    1. Thorax. 1992 Jan;47(1):34-40 - PubMed